Search
cAd3-Marburg vaccine
go.drugbank.com/drugs/DB22520InvestigationalcAd3-Marburg vaccine is under investigation in clinical trial NCT06620003 (A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored
2'-Deoxyuridine
go.drugbank.com/drugs/DB02256InvestigationalAn antimetabolite that is converted to deoxyuridine triphosphate during DNA synthesis.
Ginsenoside Rg1
go.drugbank.com/drugs/DB06750ExperimentalNutraceuticalGinsenosides have been the target of research, as they are viewed as the active compounds behind the claims of ginseng's efficacy. … Ginsenosides are a class of steroid glycosides, and triterpene saponins, found exclusively in the plant genus Panax (ginseng).
Synonyms: Panaxoside A, Ginsenoside A2Briakinumab
go.drugbank.com/drugs/DB05459InvestigationalBriakinumab is a human anti-IL-12 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases. … As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe.
Enrofloxacin
go.drugbank.com/drugs/DB11404InvestigationalVet approvedEnrofloxacin is an antibiotic agent from the fluoroquinolone family produced by the Bayer Corporation. Enrofloxacin is approved by the FDA for its veterinary use.
ANA975
go.drugbank.com/drugs/DB06490ExperimentalANA975 is a toll-like receptor 7 agonist that is developed for the treatment of hepatitis C.
Synonyms: AN 975Atibuclimab
go.drugbank.com/drugs/DB06546InvestigationalAtibuclimab (IC14) is a chimeric CD14 antibody investigated for the treatment of patients with severe sepsis.
Imgatuzumab
go.drugbank.com/drugs/DB14884InvestigationalImgatuzumab is under investigation in clinical trial NCT01326000 (A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With
Alobresib
go.drugbank.com/drugs/DB14970InvestigationalAlobresib is under investigation in clinical trial NCT02607228 (Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Participants